JP2024063143A5 - - Google Patents
Info
- Publication number
- JP2024063143A5 JP2024063143A5 JP2024030700A JP2024030700A JP2024063143A5 JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5 JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutically acceptable
- acceptable salt
- composition
- need
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678025P | 2018-05-30 | 2018-05-30 | |
| US62/678,025 | 2018-05-30 | ||
| US201862726612P | 2018-09-04 | 2018-09-04 | |
| US62/726,612 | 2018-09-04 | ||
| US201962822336P | 2019-03-22 | 2019-03-22 | |
| US62/822,336 | 2019-03-22 | ||
| GC201937661 | 2019-05-28 | ||
| GC2019/37661 | 2019-05-28 | ||
| PCT/US2019/034505 WO2019232120A1 (en) | 2018-05-30 | 2019-05-30 | Pharmaceutically acceptable salts of sepiapterin |
| JP2020566701A JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Division JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024063143A JP2024063143A (ja) | 2024-05-10 |
| JP2024063143A5 true JP2024063143A5 (https=) | 2026-02-20 |
| JP7841008B2 JP7841008B2 (ja) | 2026-04-06 |
Family
ID=68699017
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
| JP2024030700A Active JP7841008B2 (ja) | 2018-05-30 | 2024-02-29 | セピアプテリンの薬学的に許容される塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566701A Active JP7778477B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリンの薬学的に許容される塩 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210269443A1 (https=) |
| EP (1) | EP3807279B1 (https=) |
| JP (2) | JP7778477B2 (https=) |
| KR (1) | KR20210038848A (https=) |
| CN (1) | CN112543758A (https=) |
| AU (2) | AU2019277372B2 (https=) |
| BR (1) | BR112020024332A2 (https=) |
| CA (1) | CA3102070A1 (https=) |
| CL (1) | CL2020003101A1 (https=) |
| CO (1) | CO2020016582A2 (https=) |
| IL (1) | IL279101A (https=) |
| MX (1) | MX2020012978A (https=) |
| WO (1) | WO2019232120A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072614B2 (en) | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| EP3801536B1 (en) | 2018-05-30 | 2024-07-17 | PTC Therapeutics MP, Inc. | Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| CN112654356A (zh) * | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| CN114621198B (zh) | 2020-12-11 | 2025-01-21 | 北京夏禾科技有限公司 | 有机电致发光材料及其器件 |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| EP4291196A1 (en) | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| ATE218345T1 (de) * | 1994-08-05 | 2002-06-15 | Suntory Ltd | Arzneimittel gegen spinocerebellare degeneration |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| WO2008128049A2 (en) * | 2007-04-11 | 2008-10-23 | Biomarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| IN2014DN09053A (https=) | 2012-05-07 | 2015-05-22 | Shiratori Pharm | |
| WO2017218421A1 (en) * | 2016-06-13 | 2017-12-21 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| US11130760B2 (en) * | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| US11072614B2 (en) * | 2016-11-29 | 2021-07-27 | Ptc Therapeutics Mp, Inc. | Polymorphs of sepiapterin and salts thereof |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) * | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
-
2019
- 2019-05-30 AU AU2019277372A patent/AU2019277372B2/en active Active
- 2019-05-30 CA CA3102070A patent/CA3102070A1/en active Pending
- 2019-05-30 CN CN201980050845.2A patent/CN112543758A/zh active Pending
- 2019-05-30 BR BR112020024332-9A patent/BR112020024332A2/pt unknown
- 2019-05-30 US US17/059,887 patent/US20210269443A1/en active Pending
- 2019-05-30 JP JP2020566701A patent/JP7778477B2/ja active Active
- 2019-05-30 EP EP19811127.0A patent/EP3807279B1/en active Active
- 2019-05-30 WO PCT/US2019/034505 patent/WO2019232120A1/en not_active Ceased
- 2019-05-30 KR KR1020207037815A patent/KR20210038848A/ko not_active Ceased
- 2019-05-30 MX MX2020012978A patent/MX2020012978A/es unknown
-
2020
- 2020-11-27 CL CL2020003101A patent/CL2020003101A1/es unknown
- 2020-11-30 IL IL279101A patent/IL279101A/en unknown
- 2020-12-29 CO CONC2020/0016582A patent/CO2020016582A2/es unknown
-
2024
- 2024-02-29 JP JP2024030700A patent/JP7841008B2/ja active Active
-
2025
- 2025-02-13 AU AU2025201002A patent/AU2025201002A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024063143A5 (https=) | ||
| JP2021525729A5 (https=) | ||
| JP2021527031A5 (https=) | ||
| JP2024069192A5 (https=) | ||
| JP2008540486A (ja) | Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物 | |
| NO328340B1 (no) | Synergistisk kombinasjonsmedikament av roflumilast og salmeterol samt anvendelse derav. | |
| JP2021504313A (ja) | 慢性炎症性疾患および／または自己免疫疾患の予防または治療における使用のためのビドフルジムス（Ｖｉｄｏｆｌｕｄｉｍｕｓ）の投与レジメン | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| JP2021505575A5 (https=) | ||
| US20220096475A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JPWO2022101379A5 (https=) | ||
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| JPWO2019232130A5 (https=) | ||
| CZ111897A3 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| JP2014513130A5 (https=) | ||
| JPWO2019232120A5 (https=) | ||
| JPS61286326A (ja) | パ−キンソン病治療薬 | |
| JP2019531286A5 (https=) | ||
| JP2012502105A5 (https=) | ||
| JP2004501153A5 (https=) | ||
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| US20070049599A1 (en) | Use of bh4 for the treatment of respiratory diseases | |
| JPWO2019232126A5 (https=) | ||
| JP3865450B2 (ja) | パーキンソニズム治療剤 |